SG301 placebo
Phase 3
SG301 placebo is one of 13 therapeutic programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Relapsed/refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
TALVEY
Johnson & JohnsonPhase 1
Tecvayli
Johnson & JohnsonPhase 1
PD-1 Inhibitor
Johnson & JohnsonPhase 1
SG301 placebo
HHangzhou Sumgen Biotech Co., Ltd.
Phase 3
Darzalex
Johnson & JohnsonPreclinical
Beqalzi
BBeOne Medicines
Preclinical
Kyprolis
VVirionyx Corporation Limited
Preclinical
Linvoseltamab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory Multiple Myeloma1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for SG301 placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]